Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ditte Starberg Jespersen"'
Autor:
Maria Nascimento Primo, Emil Aagaard Thomsen, Xiaohong Tan, Ditte Starberg Jespersen, Anna Amanda Schönherz, Laura Barrett Ryø, Hanne Due, Martin Bøgsted, Karen Dybkær, Jacob Giehm Mikkelsen, Yuyang Pang, Anne Stidholt Roug, Ken H. Young, Min Xiao
Publikováno v:
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy as a result of drug-specific molecular resistance. The purpose of the present study
Autor:
Ditte Starberg Jespersen, Julie Støve Bødker, Steffen Falgreen, Suzette Sørensen, Hans Erik Johnsen, Maria Bach Laursen, Martin Bøgsted, Karen Dybkær, Anna Amanda Schönherz, Linn Reinholdt, Hanne Due, Marianne Schmidt Ettrup, Rasmus Røge, Alexander Schmitz, Lykke Christina Grubach
Publikováno v:
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ', Oncotarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understoo
Autor:
Charlotte Pawlyn, Hanne Due, Mehmet Kemal Samur, Annemiek Broyl, Charles Vesteghem, Ditte Starberg Jespersen, Julie Støve Bødker, Uta Bertsch, Faith E. Davies, Anna Amanda Schönherz, Nikhil C. Munshi, Martin Agge Nørgaard, Martin Perez-Andres, Alberto Orfao, Gareth J. Morgan, Rasmus Froberg Brøndum, Tarec Christoffer El-Galaly, Martin Kaiser, Alexander Schmitz, Brian A Walker, Hans Erik Johnson, Pieter Sonneveld, Martin Bøgsted, Rajen D. Shah, Hartmut Goldschmidt, Mads Sønderkær, Karen Dybkær, Richard J. Samworth, Mark van Duin, Preben Johansen, Caroline Holm Nørgaard, David W. Johnson
Publikováno v:
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnsen, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ', Blood advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Blood advances, 2(18), 2400-2411. American Society of Hematology
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnson, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ' Blood Advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Blood advances, 2(18), 2400-2411. American Society of Hematology
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnson, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ' Blood Advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and optimize therapy. Here we prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e42706263254e82e9e883353b837adc9
https://vbn.aau.dk/da/publications/3aa38799-da66-45ad-8dbd-85e69ccdc4b9
https://vbn.aau.dk/da/publications/3aa38799-da66-45ad-8dbd-85e69ccdc4b9